Therini Raises $17M to Bring Antibody to Myelin-damaging Protein Into Trials

Therini Bio financing round

Therini Bio announced raising $17 million in a financing round to speed the development of an antibody that might treat people with inflammatory conditions, such as multiple sclerosis (MS), associated with damage to blood vessels. To read full article, click here.